Table 3. Changes in serum lipids.
| EBID→EQW (n = 62) | EQW (n = 74) | Total (n = 136) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change to W26 | Change to W52 | Baseline | Change to W26 | Change to W52 | Baseline | Change to W26 | Change to W52 | |
| Total cholesterol (mg/dL) | 195 (29) | −7 (26) | −10 (24) | 193 (32) | −8 (22) | 0 (28) | 194 (31) | −8 (24) | −5 (27) |
| HDLC (mg/dL) | 55 (13) | −3 (7) | −1 (7) | 56 (15) | −2 (7) | −1 (6) | 56 (14) | −2 (7) | −1 (6) |
| LDLC (mg/dL) | 113 (30) | −3 (22) | −9 (21) | 110 (30) | −5 (23) | +1 (25) | 111 (30) | −4 (22) | −3 (24) |
| Triglycerides(mg/dL) | 135 (60) | −3 (44) | 0 (45) | 138 (68) | −4 (55) | −4 (58) | 137 (64) | −4 (50) | −2 (53) |
Data are presented as mean (standard deviation). EBID, 10 mcg exenatide b.i.d.; EBID→EQW, patients assigned to 10 mcg exenatide b.i.d. during the initial 26‐week study who were switched to exenatide once weekly for the extended 26 weeks; EQW, 2 mcg exenatide once weekly; HDLC, high‐density lipoprotein cholesterol; LDLC, low‐density lipoprotein cholesterol; W26, week 26; W52, week 52.